Full metadata record
DC FieldValueLanguage
dc.creatorAlfaro, C. (Carlos)-
dc.creatorPerez-Gracia, J.L. (Jose Luis)-
dc.creatorSuarez, N. (Natalia)-
dc.creatorRodriguez, J. (Javier)-
dc.creatorFernandez-Sanmamed, M. (Miguel)-
dc.creatorSangro, B. (Bruno)-
dc.creatorMartin-Algarra, S. (Salvador)-
dc.creatorCalvo, A. (Alfonso)-
dc.creatorRedrado, M. (Miriam)-
dc.creatorAgliano, A. (Alice)-
dc.creatorGonzalez-Hernandez, A. (Alvaro)-
dc.creatorRodriguez, I. (Inmaculada)-
dc.creatorBolaños, E. (Elixabet)-
dc.creatorHervas-Stubbs, S. (Sandra)-
dc.creatorPerez-Calvo, J. (Javier)-
dc.creatorBenito, A. (Alberto)-
dc.creatorPeñuelas-Sanchez, I. (Ivan)-
dc.creatorVigil, C. (Carmen)-
dc.creatorRichter, J.A. (José Ángel)-
dc.creatorMartinez-Forero, I. (Iván)-
dc.creatorMelero, I. (Ignacio)-
dc.identifier.citationAlfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011 Dec 1;187(11):6130-6142.es_ES
dc.description.abstractTwenty-four patients with metastatic cancer received two cycles of four daily immunizations with monocyte-derived dendritic cells (DC). DC were incubated with preheated autologous tumor lysate and subsequently with IFN-α, TNF-α, and polyinosinic:polycytidylic acid to attain type 1 maturation. One DC dose was delivered intranodally, under ultrasound control, and the rest intradermally in the opposite thigh. Cyclophosphamide (day -7), GM-CSF (days 1-4), and pegIFN alpha-2a (days 1 and 8) completed each treatment cycle. Pretreatment with cyclophosphamide decreased regulatory T cells to levels observed in healthy subjects both in terms of percentage and in absolute counts in peripheral blood. Treatment induced sustained elevations of IL-12 in serum that correlated with the output of IL-12p70 from cultured DC from each individual. NK activity in peripheral blood was increased and also correlated with the serum concentration of IL-12p70 in each patient. Circulating endothelial cells decreased in 17 of 18 patients, and circulating tumor cells markedly dropped in 6 of 19 cases. IFN-γ-ELISPOT responses to DC plus tumor lysate were observed in 4 of 11 evaluated cases. Tracing DC migration with [(111)In] scintigraphy showed that intranodal injections reached deeper lymphatic chains in 61% of patients, whereas with intradermal injections a small fraction of injected DC was almost constantly shown to reach draining inguinal lymph nodes. Five patients experienced disease stabilization, but no objective responses were documented. This combinatorial immunotherapy strategy is safe and feasible, and its immunobiological effects suggest potential activity in patients with minimal residual disease. A randomized trial exploring this hypothesis is currently ongoing.es_ES
dc.publisherAmerican Association of Immunologistses_ES
dc.subjectMetastatic Canceres_ES
dc.subjectClinical Triales_ES
dc.subjectDendritic Cellses_ES
dc.titlePilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patientses_ES

Files in This Item:
There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.